Does the media prefer ARVN or MLYS?

In the previous week, Mineralys Therapeutics had 12 more articles in the media than Arvinas. MarketBeat recorded 14 mentions for Mineralys Therapeutics and 2 mentions for Arvinas. Arvinas' average media sentiment score of 0.77 beat Mineralys Therapeutics' score of 0.49 indicating that Arvinas is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, ZLAB or ARVN?

Arvinas has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zai Lab $460.16M 4.56 -$175.54M -$1.62 N/A Arvinas $262.60M 2.00 -$80.80M -$3.32 N/A

Is ZLAB or ARVN more profitable?

Zai Lab has a net margin of -39.29% compared to Arvinas' net margin of -247.54%. Zai Lab's return on equity of -24.32% beat Arvinas' return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -39.29% -24.32% -15.52% Arvinas -247.54% -44.38% -28.38%

Which has stronger earnings and valuation, ARVN or VCEL?

Vericel has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arvinas $262.60M 2.00 -$80.80M -$3.32 N/A Vericel $276.26M 7.47 $16.52M $0.42 96.17

Is ARVN or VCEL more profitable?

Vericel has a net margin of 7.35% compared to Arvinas' net margin of -247.54%. Vericel's return on equity of 6.41% beat Arvinas' return on equity. Company Net Margins Return on Equity Return on Assets Arvinas -247.54% -44.38% -28.38% Vericel 7.35% 6.41% 4.61%

Does the media refer more to ARVN or VCEL?

In the previous week, Arvinas and Arvinas both had 2 articles in the media. Arvinas' average media sentiment score of 0.77 beat Vericel's score of -0.08 indicating that Arvinas is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, HCM or ARVN?

HUTCHMED has higher revenue and earnings than Arvinas. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 3.23 $456.91M N/A N/A Arvinas $262.60M 2.00 -$80.80M -$3.32 N/A

Is HCM or ARVN more profitable?

HUTCHMED has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. HUTCHMED's return on equity of 0.00% beat Arvinas' return on equity. Company Net Margins Return on Equity Return on Assets HUTCHMED N/A N/A N/A Arvinas -247.54% -44.38% -28.38%

Does the media refer more to HCM or ARVN?

In the previous week, Arvinas had 1 more articles in the media than HUTCHMED. MarketBeat recorded 2 mentions for Arvinas and 1 mentions for HUTCHMED. Arvinas' average media sentiment score of 0.77 beat HUTCHMED's score of -0.13 indicating that Arvinas is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arvinas 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arvinas (ARVN) Competitors

$8.14 +0.40 (+5.17%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$8.27 +0.13 (+1.60%)

As of 04:44 AM Eastern

Compare

ARVN vs. MLYS, ZLAB, VCEL, HCM, and LKFT

Should you buy Arvinas stock or one of its competitors? MarketBeat compares Arvinas with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arvinas include Mineralys Therapeutics (MLYS), Zai Lab (ZLAB), Vericel (VCEL), HUTCHMED (HCM), and Lakefront Biotherapeutics American Depositary Shares (LKFT). These companies are all part of the "pharmaceutical products" industry.

How does Arvinas compare to Mineralys Therapeutics?

Arvinas (NASDAQ:ARVN) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

95.2% of Arvinas shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 7.3% of Arvinas shares are held by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Arvinas has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

Arvinas has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	2.00	-$80.80M	-$3.32	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

In the previous week, Mineralys Therapeutics had 12 more articles in the media than Arvinas. MarketBeat recorded 14 mentions for Mineralys Therapeutics and 2 mentions for Arvinas. Arvinas' average media sentiment score of 0.77 beat Mineralys Therapeutics' score of 0.49 indicating that Arvinas is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mineralys Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Mineralys Therapeutics has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Mineralys Therapeutics' return on equity of -27.92% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

Arvinas presently has a consensus price target of $15.42, indicating a potential upside of 89.39%. Mineralys Therapeutics has a consensus price target of $49.33, indicating a potential upside of 92.63%. Given Mineralys Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Mineralys Therapeutics is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Mineralys Therapeutics beats Arvinas on 8 of the 15 factors compared between the two stocks.

How does Arvinas compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Arvinas (NASDAQ:ARVN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Zai Lab presently has a consensus price target of $45.83, indicating a potential upside of 147.88%. Arvinas has a consensus price target of $15.42, indicating a potential upside of 89.39%. Given Zai Lab's stronger consensus rating and higher probable upside, analysts clearly believe Zai Lab is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

Arvinas has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	4.56	-$175.54M	-$1.62	N/A
Arvinas	$262.60M	2.00	-$80.80M	-$3.32	N/A

Zai Lab has a net margin of -39.29% compared to Arvinas' net margin of -247.54%. Zai Lab's return on equity of -24.32% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-39.29%	-24.32%	-15.52%
Arvinas	-247.54%	-44.38%	-28.38%

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 4.9% of Zai Lab shares are held by company insiders. Comparatively, 7.3% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Arvinas had 2 more articles in the media than Zai Lab. MarketBeat recorded 2 mentions for Arvinas and 0 mentions for Zai Lab. Arvinas' average media sentiment score of 0.77 beat Zai Lab's score of 0.00 indicating that Arvinas is being referred to more favorably in the news media.

Company	Overall Sentiment
Zai Lab	Neutral
Arvinas	Positive

Zai Lab has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Arvinas has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market.

Summary

Zai Lab beats Arvinas on 9 of the 17 factors compared between the two stocks.

How does Arvinas compare to Vericel?

Arvinas (NASDAQ:ARVN) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Vericel has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	2.00	-$80.80M	-$3.32	N/A
Vericel	$276.26M	7.47	$16.52M	$0.42	96.17

Vericel has a net margin of 7.35% compared to Arvinas' net margin of -247.54%. Vericel's return on equity of 6.41% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
Vericel	7.35%	6.41%	4.61%

95.2% of Arvinas shares are owned by institutional investors. 7.3% of Arvinas shares are owned by insiders. Comparatively, 7.6% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Arvinas currently has a consensus target price of $15.42, indicating a potential upside of 89.39%. Vericel has a consensus target price of $52.50, indicating a potential upside of 29.98%. Given Arvinas' stronger consensus rating and higher possible upside, analysts plainly believe Arvinas is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46
Vericel	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Arvinas and Arvinas both had 2 articles in the media. Arvinas' average media sentiment score of 0.77 beat Vericel's score of -0.08 indicating that Arvinas is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arvinas has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market. Comparatively, Vericel has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Summary

Vericel beats Arvinas on 9 of the 15 factors compared between the two stocks.

How does Arvinas compare to HUTCHMED?

HUTCHMED (NASDAQ:HCM) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

HUTCHMED has higher revenue and earnings than Arvinas.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	3.23	$456.91M	N/A	N/A
Arvinas	$262.60M	2.00	-$80.80M	-$3.32	N/A

HUTCHMED has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. HUTCHMED's return on equity of 0.00% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Arvinas	-247.54%	-44.38%	-28.38%

HUTCHMED presently has a consensus price target of $16.80, suggesting a potential upside of 65.35%. Arvinas has a consensus price target of $15.42, suggesting a potential upside of 89.39%. Given Arvinas' stronger consensus rating and higher possible upside, analysts plainly believe Arvinas is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 3.6% of HUTCHMED shares are held by company insiders. Comparatively, 7.3% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Arvinas had 1 more articles in the media than HUTCHMED. MarketBeat recorded 2 mentions for Arvinas and 1 mentions for HUTCHMED. Arvinas' average media sentiment score of 0.77 beat HUTCHMED's score of -0.13 indicating that Arvinas is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arvinas	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HUTCHMED has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Arvinas has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market.

Summary

Arvinas beats HUTCHMED on 8 of the 15 factors compared between the two stocks.

How does Arvinas compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $36.50, suggesting a potential upside of 25.65%. Arvinas has a consensus target price of $15.42, suggesting a potential upside of 89.39%. Given Arvinas' stronger consensus rating and higher probable upside, analysts plainly believe Arvinas is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.13
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Arvinas	-247.54%	-44.38%	-28.38%

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 7.3% of Arvinas shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Arvinas. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.52	$363.05M	-$1.41	N/A
Arvinas	$262.60M	2.00	-$80.80M	-$3.32	N/A

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Arvinas has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market.

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 1 more articles in the media than Arvinas. MarketBeat recorded 3 mentions for Lakefront Biotherapeutics American Depositary Shares and 2 mentions for Arvinas. Arvinas' average media sentiment score of 0.77 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.46 indicating that Arvinas is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arvinas	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arvinas beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 17 factors compared between the two stocks.

Get Arvinas News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARVN vs. The Competition

Export

Metric	Arvinas	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$499.39M	$3.45B	$6.44B	$12.38B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-2.45	19.75	24.67	23.99
Price / Sales	2.00	330.65	528.41	106.93
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	1.20	8.29	10.76	6.50
Net Income	-$80.80M	$23.85M	$3.56B	$336.88M
7 Day Performance	6.13%	2.87%	1.03%	-0.14%
1 Month Performance	-10.45%	2.19%	0.45%	0.77%
1 Year Performance	5.17%	55.48%	29.69%	28.49%

Arvinas Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARVN Arvinas	3.4555 of 5 stars	$8.14 +5.2%	$15.42 +89.4%	+10.0%	$499.39M	$262.60M	N/A	420
MLYS Mineralys Therapeutics	3.8114 of 5 stars	$23.92 +1.3%	$49.33 +106.2%	+86.0%	$1.95B	N/A	N/A	28
ZLAB Zai Lab	1.7983 of 5 stars	$17.73 +3.9%	$45.83 +158.5%	-48.7%	$1.94B	$460.16M	N/A	1,784	Gap Up
VCEL Vericel	3.3607 of 5 stars	$38.29 +2.2%	$55.40 +44.7%	-3.4%	$1.91B	$276.26M	91.17	300	News Coverage Insider Trade
HCM HUTCHMED	3.0422 of 5 stars	$10.83 -1.2%	$16.80 +55.1%	-33.2%	$1.91B	$548.51M	N/A	1,796

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARVN) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arvinas (ARVN) Competitors

ARVN vs. MLYS, ZLAB, VCEL, HCM, and LKFT

How does Arvinas compare to Mineralys Therapeutics?

Summary

How does Arvinas compare to Zai Lab?

Summary

How does Arvinas compare to Vericel?

Summary

How does Arvinas compare to HUTCHMED?

Summary

How does Arvinas compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN vs. The Competition

Arvinas Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arvinas (ARVN) Competitors

ARVN vs. MLYS, ZLAB, VCEL, HCM, and LKFT

How does Arvinas compare to Mineralys Therapeutics?

Do institutionals and insiders believe in ARVN or MLYS?

Which has more volatility & risk, ARVN or MLYS?

Which has preferable valuation & earnings, ARVN or MLYS?

Does the media prefer ARVN or MLYS?

Is ARVN or MLYS more profitable?

Do analysts recommend ARVN or MLYS?

Summary

How does Arvinas compare to Zai Lab?

Do analysts recommend ZLAB or ARVN?

Which has preferable valuation & earnings, ZLAB or ARVN?

Is ZLAB or ARVN more profitable?

Do institutionals & insiders believe in ZLAB or ARVN?

Does the media refer more to ZLAB or ARVN?

Which has more volatility and risk, ZLAB or ARVN?

Summary

How does Arvinas compare to Vericel?

Which has stronger earnings and valuation, ARVN or VCEL?

Is ARVN or VCEL more profitable?

Do institutionals and insiders believe in ARVN or VCEL?

Do analysts recommend ARVN or VCEL?

Does the media refer more to ARVN or VCEL?

Which has more risk & volatility, ARVN or VCEL?

Summary

How does Arvinas compare to HUTCHMED?

Which has stronger valuation & earnings, HCM or ARVN?

Is HCM or ARVN more profitable?

Do analysts rate HCM or ARVN?

Do institutionals & insiders hold more shares of HCM or ARVN?

Does the media refer more to HCM or ARVN?

Which has more risk & volatility, HCM or ARVN?

Summary

How does Arvinas compare to Lakefront Biotherapeutics American Depositary Shares?

Do analysts recommend LKFT or ARVN?

Is LKFT or ARVN more profitable?

Do insiders & institutionals hold more shares of LKFT or ARVN?

Which has stronger earnings & valuation, LKFT or ARVN?

Which has more volatility and risk, LKFT or ARVN?

Does the media favor LKFT or ARVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN vs. The Competition

Arvinas Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools